Laekna (SEHK:2105) Stock Price Sinks Despite Sharp Loss Reduction

Laekna shares closed at HK$6.26 on Wednesday, capping a choppy three months in which the stock has fallen sharply despite analysts pointing to very large implied upside. The H1 2026 earnings print sharpened that tension. The company is still loss making, yet the headline story this half is how small the loss has become relative to its revenue base.

Laekna booked revenue of C¥150.3m in the first half of 2026 and reported a basic loss per share of C¥0.01, alongside a net loss of C¥2.5m. For a biotech that is priced off future pipelines, that kind of narrowing loss drew attention today.

Love Laekna's shrinking loss but concerned about backing a stock that is still loss making? Check out our hand picked 293 resilient stocks with low risk scores for ideas that pair business resilience with tighter risk profiles.

H1 2026 Earnings Summary

• Revenue (H1 2026 vs H1 2025): C¥150.28m vs C¥4.51m (very large increase, more than 30x higher)
• Net Loss (H1 2026 vs H1 2025): C¥2.55m loss vs C¥129.64m loss (loss narrowed by about 98%)
• Basic EPS (H1 2026 vs H1 2025): C¥0.01 loss per share vs C¥0.35 loss per share (loss per share narrowed by about 97%)
• Pipeline Breadth (Trailing 12 Months to H2 2025): 3 products in Phase I, 3 in Phase II, and 1 in Phase III, highlighting the development depth behind Laekna’s revenue base

Prefer clean visuals over scrolling through pages of small print and raw figures? See Laekna’s full financial picture, including a clear view of its recent loss profile and revenue base, in our company report for Laekna.

Laekna’s Revenue Step Change Reinforces Optimistic Angle

The latest half-year numbers give Laekna’s supporters something concrete. Revenue of C¥150.3m now sits against a very small net loss of C¥2.5m and a basic loss per share of C¥0.01. For a company still framed as clinical stage, that shift toward a much tighter income statement supports the idea that the business model is gaining operational substance. The broad pipeline, including oncology and obesity assets, now rests on a revenue base that is starting to matter rather than a purely story driven platform.

Residual Losses Keep Risk Arguments Alive For Laekna

For more cautious investors, Laekna’s report still leaves key questions open. The company remains loss making, even if the loss has narrowed sharply. That keeps funding and dilution risk on the table, especially with several products in Phase I and Phase II that will continue to require capital. The share price performance over 90 days, with a decline of about 45%, also shows the market has not treated the stock as de risked. The financial trend is improving, but the business still sits in a high uncertainty bracket.

Expose whether Laekna's recent loss reduction is the full story or an early warning. Review the independent risk analysis for Laekna which shows 3 important warning signs

Take Charge Of Your Next Move

If Laekna’s sharp loss reduction has caught your attention but the recent share price decline leaves you cautious, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch for a more comfortable entry point. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the most important updates that may affect your holdings. For a broader view, tap into crowd insights and different angles on Laekna and similar stocks through the Community. This can help you identify potential catalysts and risks early and give yourself a better chance of staying informed about the market.

Curious About Alternatives Before Committing

Fresh ideas can move quickly when momentum builds and early interest starts flying. Scan potential breakouts while they are still under the radar and consider them carefully.

• Spot companies with strong cash generation and solid footing by reviewing a curated 271 high quality undervalued stocks before the crowd catches on and prices in the quality.
• Track the companies involved in AI infrastructure and use the focused 55 AI infrastructure stocks while these themes are still developing and under followed.
• Zero in on producers linked to gold price movements with the curated 32 elite gold producer stocks and monitor shifting momentum and potential entry points.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com